Molecular targeting of angiogenesis for imaging and therapy

[1]  Yan Li,et al.  Subtractive proteomic mapping of the endothelial surface in lung and solid tumours for tissue-specific therapy , 2004, Nature.

[2]  J. Berlin,et al.  Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. , 2004, The New England journal of medicine.

[3]  D. Neri,et al.  Engineering a thermostable human prolyl endopeptidase for antibody-directed enzyme prodrug therapy. , 2004, Biochemistry.

[4]  Kenneth J. Hillan,et al.  Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer , 2004, Nature Reviews Drug Discovery.

[5]  Christoph E. Dumelin,et al.  Encoded self-assembling chemical libraries , 2004, Nature Biotechnology.

[6]  Michelle R. Arkin,et al.  Small-molecule inhibitors of protein–protein interactions: progressing towards the dream , 2004, Nature Reviews Drug Discovery.

[7]  R. Begent,et al.  Directed evolution of an anti-carcinoembryonic antigen scFv with a 4-day monovalent dissociation half-time at 37°C , 2004 .

[8]  K. Grosios,et al.  Angiogenesis inhibition by the novel VEGF receptor tyrosine kinase inhibitor, PTK787/ZK222584, causes significant anti-arthritic effects in models of rheumatoid arthritis , 2004, Inflammation Research.

[9]  K. Heider,et al.  CD44v6: a target for antibody-based cancer therapy , 2004, Cancer Immunology, Immunotherapy.

[10]  L. Jermutus,et al.  Combinatorial protein biochemistry for therapeutics and proteomics. , 2004, Current pharmaceutical biotechnology.

[11]  H. Kosmehl,et al.  This is an author version of the contribution published on: Questa è la versione dell’autore dell’opera: Selective targeted delivery of TNFα to tumor blood vessels , 2022 .

[12]  P. Parren,et al.  Resolution of psoriasis upon blockade of IL-15 biological activity in a xenograft mouse model. , 2003, The Journal of clinical investigation.

[13]  S. Vallabhajosula,et al.  Targeting metastatic prostate cancer with radiolabeled monoclonal antibody J591 to the extracellular domain of prostate specific membrane antigen. , 2003, The Journal of urology.

[14]  N. Bander,et al.  Targeted systemic therapy of prostate cancer with a monoclonal antibody to prostate-specific membrane antigen. , 2003, Seminars in oncology.

[15]  G. Sledge,et al.  A phase I/II dose-escalation trial of bevacizumab in previously treated metastatic breast cancer. , 2003, Seminars in oncology.

[16]  R. Reddel,et al.  Mammalian stanniocalcins and cancer. , 2003, Endocrine-related cancer.

[17]  W. Oyen,et al.  Phase I therapy study with (186)Re-labeled humanized monoclonal antibody BIWA 4 (bivatuzumab) in patients with head and neck squamous cell carcinoma. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[18]  J. Pastorek,et al.  Biodistribution and pharmacokinetics of 125I‐labeled monoclonal antibody M75 specific for carbonic anhydrase IX, an intrinsic marker of hypoxia, in nude mice xenografted with human colorectal carcinoma , 2003, International journal of cancer.

[19]  S. Stoeckli,et al.  Expression of the Extra Domain B of Fibronectin, a Marker of Angiogenesis, in Head and Neck Tumors , 2003, The Laryngoscope.

[20]  Dario Neri,et al.  Synergistic therapeutic effects of a tumor targeting antibody fragment, fused to interleukin 12 and to tumor necrosis factor alpha. , 2003, Cancer research.

[21]  Y. Ogura,et al.  Leukocytes mediate retinal vascular remodeling during development and vaso-obliteration in disease , 2003, Nature Medicine.

[22]  P. Carmeliet.  Angiogenesis in health and disease , 2003, Nature Medicine.

[23]  R. Hynes,et al.  Physiological levels of tumstatin, a fragment of collagen IV alpha3 chain, are generated by MMP-9 proteolysis and suppress angiogenesis via alphaV beta3 integrin. , 2003, Cancer cell.

[24]  N. Ferrara,et al.  The biology of VEGF and its receptors , 2003, Nature Medicine.

[25]  L. Benjamin,et al.  Angiogenesis: Tumorigenesis and the angiogenic switch , 2003, Nature Reviews Cancer.

[26]  P. Ratcliffe,et al.  Regulation of angiogenesis by hypoxia: role of the HIF system , 2003, Nature Medicine.

[27]  S. Klußmann,et al.  Toward third-generation aptamers: Spiegelmers and their therapeutic prospects. , 2003, Current opinion in drug discovery & development.

[28]  P. Oh,et al.  Transient Mechanoactivation of Neutral Sphingomyelinase in Caveolae to Generate Ceramide* , 2003, The Journal of Biological Chemistry.

[29]  Dario Neri,et al.  Immunoscintigraphic detection of the ED-B domain of fibronectin, a marker of angiogenesis, in patients with cancer. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[30]  L. Green,et al.  Antibody discovery: the use of transgenic mice to generate human monoclonal antibodies for therapeutics. , 2002, Current opinion in biotechnology.

[31]  C. Halin,et al.  An antibody-calmodulin fusion protein reveals a functional dependence between macromolecular isoelectric point and tumor targeting performance. , 2002, International journal of radiation oncology, biology, physics.

[32]  C. Halin,et al.  Tumor‐targeting properties of antibody–vascular endothelial growth factor fusion proteins , 2002, International journal of cancer.

[33]  S. Ran,et al.  Increased exposure of anionic phospholipids on the surface of tumor blood vessels. , 2002, Cancer research.

[34]  G. Viale,et al.  Differentiation between high- and low-grade astrocytoma using a human recombinant antibody to the extra domain-B of fibronectin. , 2002, The American journal of pathology.

[35]  L. Zardi,et al.  Selective targeting of tumoral vasculature: Comparison of different formats of an antibody (L19) to the ED‐B domain of fibronectin , 2002, International journal of cancer.

[36]  D. Monroe,et al.  Platelets and thrombin generation. , 2002, Arteriosclerosis, thrombosis, and vascular biology.

[37]  M. Matsumura,et al.  Unbalanced vitreous levels of pigment epithelium-derived factor and vascular endothelial growth factor in diabetic retinopathy. , 2002, American journal of ophthalmology.

[38]  Franklin Peale,et al.  In silico data filtering to identify new angiogenesis targets from a large in vitro gene profiling data set. , 2002, Physiological genomics.

[39]  R. Schwendener,et al.  Cytotoxic targeting of F9 teratocarcinoma tumours with anti-ED-B fibronectin scFv antibody modified liposomes , 2002, British Journal of Cancer.

[40]  C. Halin,et al.  Quantitation of the tumor-targeting properties of antibody fragments conjugated to cell-permeating HIV-1 TAT peptides. , 2002, Bioconjugate chemistry.

[41]  Michael Gorn,et al.  Magic roundabout is a new member of the roundabout receptor family that is endothelial specific and expressed at sites of active angiogenesis. , 2002, Genomics.

[42]  K. Ishibashi,et al.  Prospect of a stanniocalcin endocrine/paracrine system in mammals. , 2002, American journal of physiology. Renal physiology.

[43]  R. Coleman,et al.  Phase II trial of murine (131)I-labeled antitenascin monoclonal antibody 81C6 administered into surgically created resection cavities of patients with newly diagnosed malignant gliomas. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[44]  C. Halin,et al.  Enhancement of the antitumor activity of interleukin-12 by targeted delivery to neovasculature , 2002, Nature Biotechnology.

[45]  H. Kosmehl,et al.  Enhancement of the antitumor properties of interleukin-2 by its targeted delivery to the tumor blood vessel extracellular matrix. , 2002, Blood.

[46]  C. Kahn,et al.  Tumstatin, an Endothelial Cell-Specific Inhibitor of Protein Synthesis , 2002, Science.

[47]  P. Janmey,et al.  Involvement of phosphatidylinositol 4,5-bisphosphate in phosphatidylserine exposure in platelets: use of a permeant phosphoinositide-binding peptide. , 2001, Biochemistry.

[48]  L. Zardi,et al.  Lack of specificity of endoglin expression for tumor blood vessels , 2001, International journal of cancer.

[49]  M. Feldmann,et al.  Raised serum vascular endothelial growth factor levels are associated with destructive change in inflammatory arthritis. , 2001, Arthritis and rheumatism.

[50]  P. Schellhammer,et al.  Quantitation of serum prostate-specific membrane antigen by a novel protein biochip immunoassay discriminates benign from malignant prostate disease. , 2001, Cancer research.

[51]  J. Wadenbäck,et al.  Cosmix-plexing: a novel recombinatorial approach for evolutionary selection from combinatorial libraries. , 2001, Journal of biotechnology.

[52]  Andrea Scozzafava,et al.  Carbonic anhydrase inhibitors. , 2001, Medicinal research reviews.

[53]  D. Spencer,et al.  A strategy for antitumor vascular therapy by targeting the vascular endothelial growth factor: receptor complex. , 2001, Cancer research.

[54]  M A Konerding,et al.  3D microvascular architecture of pre-cancerous lesions and invasive carcinomas of the colon , 2001, British Journal of Cancer.

[55]  M. Lebwohl,et al.  Altered expression of angiopoietins and Tie2 endothelium receptor in psoriasis. , 2001, The Journal of investigative dermatology.

[56]  Michael I. Wilson,et al.  Targeting of HIF-α to the von Hippel-Lindau Ubiquitylation Complex by O2-Regulated Prolyl Hydroxylation , 2001, Science.

[57]  M. Ivan,et al.  HIFα Targeted for VHL-Mediated Destruction by Proline Hydroxylation: Implications for O2 Sensing , 2001, Science.

[58]  J. Posey,et al.  A pilot trial of Vitaxin, a humanized anti-vitronectin receptor (anti alpha v beta 3) antibody in patients with metastatic cancer. , 2001, Cancer biotherapy & radiopharmaceuticals.

[59]  Dario Neri,et al.  Selective targeting of tumour neovasculature by a radiohalogenated human antibody fragment specific for the ED-B domain of fibronectin , 2001, European Journal of Nuclear Medicine.

[60]  J. Redondo,et al.  Selective Inhibition of Vascular Endothelial Growth Factor–Mediated Angiogenesis by Cyclosporin a , 2001, The Journal of experimental medicine.

[61]  R. Jain.  Delivery of molecular and cellular medicine to solid tumors. , 2001, Advanced drug delivery reviews.

[62]  L. Zardi,et al.  Isolation of anti-angiogenesis antibodies from a large combinatorial repertoire by colony filter screening. , 2001, Nucleic acids research.

[63]  Y. Tsutsumi,et al.  Effective Cancer Targeting Using an Anti‐tumor Tissue Vascular Endotheliumspecific Monoclonal Antibody (TES‐23) , 2000, Japanese journal of cancer research : Gann.

[64]  Andreas Plückthun,et al.  Picomolar affinity antibodies from a fully synthetic naive library selected and evolved by ribosome display , 2000, Nature Biotechnology.

[65]  M. Detmar.  The role of VEGF and thrombospondins in skin angiogenesis. , 2000, Journal of dermatological science.

[66]  Fulvio Magni,et al.  Enhancement of tumor necrosis factor α antitumor immunotherapeutic properties by targeted delivery to aminopeptidase N (CD13) , 2000, Nature Biotechnology.

[67]  K. terBrugge,et al.  Analysis of Endoglin Expression in Normal Brain Tissue and in Cerebral Arteriovenous Malformations , 2000, Stroke.

[68]  J. Minna,et al.  Selective inhibition of vascular endothelial growth factor (VEGF) receptor 2 (KDR/Flk-1) activity by a monoclonal anti-VEGF antibody blocks tumor growth in mice. , 2000, Cancer research.

[69]  R. Klemenz,et al.  Advances in Brief Increased Expression of H/T-Cadherin in Tumor-penetrating Blood Vessels 1 , 2022 .

[70]  K. Kinzler,et al.  Genes expressed in human tumor endothelium. , 2000, Science.

[71]  Erwin G. Van Meir,et al.  Thrombospondin-1 Is Downregulated by Anoxia and Suppresses Tumorigenicity of Human Glioblastoma Cells , 2000, The Journal of experimental medicine.

[72]  M. Maio,et al.  Endoglin is a suitable target for efficient imaging of solid tumors: in vivo evidence in a canine mammary carcinoma model. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[73]  R K Jain,et al.  Openings between defective endothelial cells explain tumor vessel leakiness. , 2000, The American journal of pathology.

[74]  Y. Tsutsumi,et al.  Recognition of human activated CD44 by tumor vasculature-targeted antibody. , 2000, Biochemical and biophysical research communications.

[75]  R Weissleder,et al.  Imaging of tumour neovasculature by targeting the TGF-beta binding receptor endoglin. , 2000, European journal of cancer.

[76]  L. Gold,et al.  Aptamers as therapeutic and diagnostic agents. , 2000, Journal of biotechnology.

[77]  R Pasqualini,et al.  Aminopeptidase N is a receptor for tumor-homing peptides and a target for inhibiting angiogenesis. , 2000, Cancer research.

[78]  P. Taylor,et al.  Anti-cytokine therapy for rheumatoid arthritis. , 2000, Annual review of medicine.

[79]  C. Frelin,et al.  Regulation of Vascular Endothelial Growth Factor Expression in Human Keratinocytes by Retinoids* , 2000, The Journal of Biological Chemistry.

[80]  H. Kosmehl,et al.  Distribution of laminin and fibronectin isoforms in oral mucosa and oral squamous cell carcinoma , 1999, British Journal of Cancer.

[81]  D. Hicklin,et al.  Antivascular endothelial growth factor receptor (fetal liver kinase 1) monoclonal antibody inhibits tumor angiogenesis and growth of several mouse and human tumors. , 1999, Cancer research.

[82]  V. Reuter,et al.  Prostate-specific membrane antigen is produced in tumor-associated neovasculature. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[83]  Dario Neri,et al.  Selective targeting and photocoagulation of ocular angiogenesis mediated by a phage-derived human antibody fragment , 1999, Nature Biotechnology.

[84]  W. Benedict,et al.  Pigment epithelium-derived factor: a potent inhibitor of angiogenesis. , 1999, Science.

[85]  V. Reuter,et al.  Five different anti-prostate-specific membrane antigen (PSMA) antibodies confirm PSMA expression in tumor-associated neovasculature. , 1999, Cancer research.

[86]  L. Dinkelborg,et al.  HEMOSTASIS, THROMBOSIS, AND VASCULAR BIOLOGY A High-Affinity Human Antibody That Targets Tumoral Blood Vessels , 1999 .

[87]  G. Viale,et al.  Identification of a glioblastoma-associated tenascin-C isoform by a high affinity recombinant antibody. , 1999, The American journal of pathology.

[88]  G. Goodall,et al.  Hypoxic regulation of vascular endothelial growth factor mRNA stability requires the cooperation of multiple RNA elements. , 1999, Molecular biology of the cell.

[89]  L. Zardi,et al.  Increased binding affinity and valence of recombinant antibody fragments lead to improved targeting of tumoral angiogenesis. , 1999, Cancer research.

[90]  George M Whitesides,et al.  Polyvalent Interactions in Biological Systems: Implications for Design and Use of Multivalent Ligands and Inhibitors. , 1998, Angewandte Chemie.

[91]  A. Adamis,et al.  Ocular neovascularization: an epidemiologic review. , 1998, Survey of ophthalmology.

[92]  A. Pini,et al.  Design and Use of a Phage Display Library , 1998, The Journal of Biological Chemistry.

[93]  R Pasqualini,et al.  Molecular heterogeneity of the vascular endothelium revealed by in vivo phage display. , 1998, The Journal of clinical investigation.

[94]  R. Coleman,et al.  Iodine-131-labeled antitenascin monoclonal antibody 81C6 treatment of patients with recurrent malignant gliomas: phase I trial results. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[95]  A. Koch,et al.  Angiogenesis: Implications for rheumatoid arthritis , 1998 .

[96]  R. Brekken,et al.  Vascular endothelial growth factor as a marker of tumor endothelium. , 1998, Cancer research.

[97]  David A. Cheresh,et al.  Detection of tumor angiogenesis in vivo by αvβ3-targeted magnetic resonance imaging , 1998, Nature Medicine.

[98]  H. Kroemer,et al.  Elucidation of the mechanism enabling tumor selective prodrug monotherapy. , 1998, Cancer research.

[99]  A. Koch,et al.  Angiogenesis in rheumatoid arthritis: pathogenic and clinical significance. , 1998, Journal of investigative medicine : the official publication of the American Federation for Clinical Research.

[100]  E. Ruoslahti,et al.  Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model. , 1998, Science.

[101]  Dario Neri,et al.  Targeting by affinity–matured recombinant antibody fragments of an angiogenesis associated fibronectin isoform , 1997, Nature Biotechnology.

[102]  N. Bander,et al.  Monoclonal antibodies to the extracellular domain of prostate-specific membrane antigen also react with tumor vascular endothelium. , 1997, Cancer research.

[103]  A. Plückthun,et al.  In vitro selection and evolution of functional proteins by using ribosome display. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[104]  Ulrich Keilholz,et al.  Immunohistochemical analysis of integrin αvβ3 expression on tumor‐associated vessels of human carcinomas , 1997 .

[105]  C. Dawson,et al.  Biotinylation of membrane proteins accessible via the pulmonary circulation in normal and hyperoxic rats. , 1997, The American journal of physiology.

[106]  G. Palade,et al.  Neovasculature induced by vascular endothelial growth factor is fenestrated. , 1997, Cancer research.

[107]  H. Dvorak,et al.  Vascular targeting of solid and ascites tumours with antibodies to vascular endothelial growth factor. , 1996, European journal of cancer.

[108]  P. Hajduk,et al.  Discovering High-Affinity Ligands for Proteins: SAR by NMR , 1996, Science.

[109]  A. Pini,et al.  Phage antibodies with pan‐species recognition of the oncofoetal angiogenesis marker fibronectin ED‐B domain , 1996, International journal of cancer.

[110]  Chandra L. Theesfeld,et al.  Involvement of integrins alpha v beta 3 and alpha v beta 5 in ocular neovascular diseases. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[111]  G. Semenza,et al.  Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1 , 1996, Molecular and cellular biology.

[112]  P. Schellhammer,et al.  Upregulation of prostate-specific membrane antigen after androgen-deprivation therapy. , 1996, Urology.

[113]  G. Winter,et al.  Mimicking somatic hypermutation: affinity maturation of antibodies displayed on bacteriophage using a bacterial mutator strain. , 1996, Journal of molecular biology.

[114]  T. Springer,et al.  Platelet-Mediated Lymphocyte Delivery to High Endothelial Venules , 1996, Science.

[115]  Erkki Ruoslahti,et al.  Organ targeting In vivo using phage display peptide libraries , 1996, Nature.

[116]  J. Bye,et al.  Isolation of high-affinity monomeric human anti-c-erbB-2 single chain Fv using affinity-driven selection. , 1996, Journal of molecular biology.

[117]  C. Sturiale,et al.  Local treatment of malignant gliomas by direct infusion of specific monoclonal antibodies labeled with 131I: comparison of the results obtained in recurrent and newly diagnosed tumors. , 1995, Cancer research.

[118]  A. Gazdar,et al.  Up-regulation of endoglin on vascular endothelial cells in human solid tumors: implications for diagnosis and therapy. , 1995, Clinical cancer research : an official journal of the American Association for Cancer Research.

[119]  D R Burton,et al.  CDR walking mutagenesis for the affinity maturation of a potent human anti-HIV-1 antibody into the picomolar range. , 1995, Journal of molecular biology.

[120]  D. Creamer,et al.  Altered vascular endothelium integrin expression in psoriasis. , 1995, The American journal of pathology.

[121]  David A. Cheresh,et al.  Definition of Two Angiogenic Pathways by Distinct αv Integrins , 1995, Science.

[122]  L. Aiello,et al.  Suppression of retinal neovascularization in vivo by inhibition of vascular endothelial growth factor (VEGF) using soluble VEGF-receptor chimeric proteins. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[123]  D. Lefer,et al.  Enhanced expression of intracellular adhesion molecule-1 and P-selectin in the diabetic human retina and choroid. , 1995, The American journal of pathology.

[124]  R. Hynes,et al.  Expression of the alternatively spliced EIIIB segment of fibronectin. , 1995, Cell adhesion and communication.

[125]  J. Bischoff,et al.  Approaches to studying cell adhesion molecules in angiogenesis. , 1995, Trends in cell biology.

[126]  D. Cheresh,et al.  Integrin α v β 3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels , 1994, Cell.

[127]  L. Zardi,et al.  The fibronectin isoform containing the ed‐b oncofetal domain: A marker of angiogenesis , 1994, International journal of cancer.

[128]  A Mathis,et al.  Detection of vascular endothelial growth factor messenger RNA and vascular endothelial growth factor-like activity in proliferative diabetic retinopathy. , 1994, Archives of ophthalmology.

[129]  L. Zardi,et al.  Distribution of oncofetal fibronectin isoforms in normal, hyperplastic and neoplastic human breast tissues , 1994, International journal of cancer.

[130]  H. Dvorak,et al.  Overexpression of vascular permeability factor/vascular endothelial growth factor and its receptors in psoriasis , 1994, The Journal of experimental medicine.

[131]  Joan W. Miller,et al.  Vascular endothelial growth factor/vascular permeability factor is temporally and spatially correlated with ocular angiogenesis in a primate model. , 1994, The American journal of pathology.

[132]  D. Huszar,et al.  Antigen-specific human antibodies from mice comprising four distinct genetic modifications , 1994, Nature.

[133]  F. Fazio,et al.  Pre-targeted immunodetection in glioma patients: tumour localization and single-photon emission tomography imaging of [99mTc]PnAO-biotin , 1994, European Journal of Nuclear Medicine.

[134]  V. Dixit,et al.  Aberrant production of interleukin-8 and thrombospondin-1 by psoriatic keratinocytes mediates angiogenesis. , 1994, The American journal of pathology.

[135]  F M van den Berg,et al.  Expression of CD44 variant proteins in human colorectal cancer is related to tumor progression. , 1993, Cancer research.

[136]  S. Kumar,et al.  A monoclonal antibody detects heterogeneity in vascular endothelium of tumours and normal tissues , 1993, International journal of cancer.

[137]  L. Zardi,et al.  The inclusion of the type III repeat ED-B in the fibronectin molecule generates conformational modifications that unmask a cryptic sequence. , 1992, The Journal of biological chemistry.

[138]  L. Zardi,et al.  Expression of different tenascin isoforms in normal, hyperplastic and neoplastic human breast tissues , 1992, International journal of cancer.

[139]  B. Jacobson,et al.  Isolation and partial characterization of the luminal plasmalemma of microvascular endothelium from rat lungs. , 1992, European journal of cell biology.

[140]  L. Zardi,et al.  Treatment of intracranial human glioblastoma by direct intratumoral administration of 131I‐labelled anti‐tenascin monoclonal antibody BC‐2 , 1992, International journal of cancer.

[141]  L. Zardi,et al.  Comparison of human tenascin expression in normal, simian-virus-40-transformed and tumor-derived cell lines. , 1992, European journal of biochemistry.

[142]  Harold E. Dvorak,et al.  Reappearance of an embryonic pattern of fibronectin splicing during wound healing in the adult rat , 1989, The Journal of cell biology.

[143]  L. Zardi,et al.  A tumor-associated fibronectin isoform generated by alternative splicing of messenger RNA precursors , 1989, The Journal of cell biology.

[144]  James T. Elder,et al.  Overexpression of transforming growth factor alpha in psoriatic epidermis. , 1989, Science.

[145]  F. Baralle,et al.  Transformed human cells produce a new fibronectin isoform by preferential alternative splicing of a previously unobserved exon. , 1987, The EMBO journal.

[146]  G. Weinstein,et al.  Treatment of psoriasis. , 1976, The New England journal of medicine.

[147]  C. Milstein,et al.  Continuous cultures of fused cells secreting antibody of predefined specificity , 1975, Nature.

[148]  J. Folkman.  Angiogenesis in psoriasis: therapeutic implications. , 1972, The Journal of investigative dermatology.

[149]  J. Folkman,et al.  Anti‐Angiogenesis: New Concept for Therapy of Solid Tumors , 1972, Annals of surgery.

[150]  J. Folkman.  Tumor angiogenesis: therapeutic implications. , 1971, The New England journal of medicine.

[151]  F. Fazio,et al.  Pre-targeted immunodetection in glioma patients: tumour localization and single-photon emission tomography imaging of [99mTc]PnAO-biotin , 2004, European Journal of Nuclear Medicine.

[152]  P. Petrow,et al.  Expression of fibronectin splice variants and oncofetal glycosylated fibronectin in the synovial membranes of patients with rheumatoid arthritis and osteoarthritis , 2004, Rheumatology International.

[153]  Zhen-ping Zhu,et al.  Inhibition of Tumor Growth and Metastasis by Targeting Tumor-Associated Angiogenesis with Antagonists to the Receptors of Vascular Endothelial Growth Factor , 2004, Investigational New Drugs.

[154]  D. Creamer,et al.  Angiogenesis in psoriasis , 2004, Angiogenesis.

[155]  A. Cope,et al.  Anti-TNFalpha therapy of rheumatoid arthritis: what can we learn about chronic disease? , 2004, Novartis Foundation symposium.

[156]  Rakesh K. Jain,et al.  Transport of molecules across tumor vasculature , 2004, Cancer and Metastasis Reviews.

[157]  W. Delano,et al.  In situ assembly of enzyme inhibitors using extended tethering , 2003, Nature Biotechnology.

[158]  J. Pastorek,et al.  Immunotargeting of human cervical carcinoma xenograft expressing CA IX tumor-associated antigen by 125I-labeled M75 monoclonal antibody. , 2003, Neoplasma.

[159]  R. Hynes,et al.  Physiological levels of tumstatin, a fragment of collagen IV alpha3 chain, are generated by MMP-9 proteolysis and suppress angiogenesis via alphaV beta3 integrin. , 2003, Cancer cell.

[160]  L. Zardi,et al.  Expression of extradomain-B-containing fibronectin in subretinal choroidal neovascular membranes. , 2003, American journal of ophthalmology.

[161]  Inger Sandlie,et al.  Therapeutic antibodies for human diseases at the dawn of the twenty-first century , 2003, Nature Reviews Drug Discovery.

[162]  Olof Ramström,et al.  Drug discovery by dynamic combinatorial libraries , 2002, Nature Reviews Drug Discovery.

[163]  H. Kosmehl,et al.  Targeted delivery of tissue factor to the ED-B domain of fibronectin, a marker of angiogenesis, mediates the infarction of solid tumors in mice. , 2001, Cancer research.

[164]  D. Neri,et al.  Design and use of phage display libraries for the selection of antibodies and enzymes. , 2000, Methods in enzymology.

[165]  M. Bednarski,et al.  Detection of tumor angiogenesis in vivo by alphaVbeta3-targeted magnetic resonance imaging. , 1998, Nature medicine.

[166]  D. Hanahan.  A flanking attack on cancer , 1998, Nature Medicine.

[167]  Erkki Ruoslahti,et al.  αv Integrins as receptors for tumor targeting by circulating ligands , 1997, Nature Biotechnology.

[168]  D. Ruiter,et al.  Immunohistochemical analysis of integrin alpha vbeta3 expression on tumor-associated vessels of human carcinomas. , 1997, International journal of cancer.

[169]  D. Cheresh,et al.  Definition of two angiogenic pathways by distinct alpha v integrins. , 1995, Science.

[170]  J. Folkman.  Angiogenesis in cancer, vascular, rheumatoid and other disease , 1995, Nature Medicine.

[171]  D. Cheresh,et al.  Integrin alpha v beta 3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels. , 1994, Cell.

[172]  G. Winter,et al.  Making antibodies by phage display technology. , 1994, Annual review of immunology.

[173]  G. Murphy,et al.  Monoclonal antibodies to a new antigenic marker in epithelial prostatic cells and serum of prostatic cancer patients. , 1987, Anticancer research.

[174]  P. T. Jones,et al.  Replacing the complementarity-determining regions in a human antibody with those from a mouse , 1986, Nature.